Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.


PURPOSE Although alkylators are known to be effective against some myeloid leukemias, resistance is often mediated via O6-alkylguanine-DNA alkyltransferase (AGT). Temozolomide's inhibition of AGT may sensitize leukemia cells to the novel alkylator laromustine. We conducted a phase I translational study to evaluate the toxicities and estimate the maximum… (More)
DOI: 10.3816/CLML.2010.n.033


1 Figure or Table